Home
Stampa
 
Auditorium
Polissena A Hall
Polissena B Hall
Ginevra Hall
10.00 - 13.00
Apertura Segreteria e Registrazione
14.00 - 16.30
16.30 - 17.15
Artistic contest RaccontART HIV - Incontro con le scuole finaliste

Satellite Symposium

Durable treatment success in HIV

Pre-Conference advanced course

New frontiers in medical virology

Pre-Conference advanced course

New challenges in sexually transmitted infections: sexual health, prevention and more

Pre-Conference advanced course

Nurse management of patients with comorbidities
17.15 - 19.35

Auditorium

ICAR 2020 Opening Session

17.15 - 17.45: Introducing ICAR 2020
Welcome Addresses

17.45 - 18.05: RaccontART HIV contest Awards

18.05 - 19.35: Keynote Lectures

19.35 - 22.30

Auditorium

ICAR 2020 Welcome Reception
 
  • Auditorium
    14.00-16.30

    Special event

    Artistic contest RaccontART HIV - Incontro con le scuole finaliste

    Artistic contest RaccontART HIV - Incontro con le scuole finaliste

    Chairs: F. Ceccherini - Silberstein, A. Di Biagio, R. Galipò

    16.30-17.15

    Satellite Symposium

    Durable treatment success in HIV

    Satellite Symposium

    Durable treatment success in HIV

    Thanks to the advent of increasingly effective antiretroviral drugs and the additional knowledge/experience gained, HIV infection is now a manageable chronic condition, in which the achievement of immune-viral control has become a reality for the majority of treated patients. Therefore, it becomes essential to "update" the clinicians' and patients' perspectives of the disease, targeting not only the mere control of the virus (both at the population and patient level) but also the global health of current PLWHIV. This latter aspect becomes even more crucial since patients still are vulnerable due to a residual disease driven by non-AIDS defined comorbidities. Reflecting on current challenges and available strategies to fill these gaps will be essential, also with the support of real-life data. These themes will be addressed in an interactive way, through a direct dialogue between physicians and patients.

    Chair: C. Mussini

    16.30 - 16.45 Global Health in HIV
    S. Vella
    16.45 - 17.15 Round Table "Strategies for durable treatment success"
    Participants: M. Andreoni, G. Di Perri, A. d'Arminio Monforte, G.M. Corbelli
    17.15-19.35

    ICAR 2020 Opening Session

    17.15 - 17.45: Introducing ICAR 2020
    Welcome Addresses

    17.45 - 18.05: RaccontART HIV contest Awards

    18.05 - 19.35: Keynote Lectures

    ICAR 2020 Opening Session

    17.15 - 17.45 Introducing ICAR 2020
    Chairs: M. Clementi, S. Mattioli, C. Mussini, G. Silvestri, M. Tavio
    17.15 - 17.30 Introducing ICAR 2020
    17.30 - 17.45 Authorities' welcome addresses
    17.45 - 18.05 RaccontART HIV contest Awards
    Chairs: A. Caraglia, M. Errico, A. Lazzarin
    18.05 - 19.05 Keynote Lectures
    Chairs: G.V. Calvino, A. Cossarizza, C.F. Perno, S. Vella
    18.05 - 18.35 Mauro Moroni Memorial Lecture "Immune control to reservoir: commencing countdown, control on"
    M. Paiardini
    18.35 - 19.05 Transgender, non-binary and HIV people: peculiarities of a key population between stigma and retaining in care
    O. Voza
    19.05 - 19.35 The public health response to new and future pandemics: lights and shadows from COVID-19
    G. Ippolito
    19.35-22.30 ICAR 2020 Welcome Reception

    ICAR 2020 Welcome Reception

  • Polissena A Hall
    14.00-16.30

    Pre-Conference advanced course

    New frontiers in medical virology

    Pre-Conference advanced course

    New frontiers in medical virology

    Infectious diseases are of public interest because of their impact on human, animal, and plant health. In this context, viruses play a central role in all aspects of medical research, ranging from molecular biology and immunology to evolution and epidemiology. The course will offer insight into the laboratory tools for the surveillance, diagnosis and monitoring of viral infections. It will also focus on novel aspects of viral pathogenesis and elaboration of therapeutic strategies.

    Chairs: I. Bon, B. Rossetti, C. Tincati

    14.00 - 14.30 Next-generation sequencing: a methodology changing the way to understand genome sequencing, evolution, ecology and discovery viruses
    N. Clementi
    14.30 - 15.00 Serological and molecular tools for detection of emerging viruses
    G. Rossini
    15.00 - 15.30 Role of HIV-1 protein variants in lymphoma pathogenesis
    F. Caccuri
    15.30 - 16.00 New frontiers of antiviral strategies
    O. Turriziani
    16.00 - 16.30 Discussion and conclusions
  • Polissena B Hall
    14.00-16.30

    Pre-Conference advanced course

    New challenges in sexually transmitted infections: sexual health, prevention and more

    Pre-Conference advanced course

    New challenges in sexually transmitted infections: sexual health, prevention and more

    The consequences of sexually transmitted infections (STIs) on both individual and public health can be severe. The increasing incidence of STIs demands a call to action to ensure that populations at risk have access to comprehensive STIs prevention and care, especially in the context of expanded use of pre-exposure prophylaxis (PrEP) for HIV prevention. Integration of STIs services and PrEP is challenging but also provides a unique opportunity to optimize broader sexual and reproductive health services.

    Chairs: L. Badia, G. Cuomo, R. Rossotti

    14.00 - 14.30 Beyond PrEP: from a clinical management of STIs to a broader approach to sexual health
    M. Cordioli
    14.30 - 15.00 Test and Same Day Treatment in HIV: the role of screening and early ART initiation in the management of HIV
    A. Ciccullo
    15.00 - 15.30 Empowering people for their sexual health: how U=U changed the sexual lives of people living with HIV
    D. Calzavara
    15.30 - 16.00 Focus on vaccinations: are they an effective tool of sexual prevention?
    M. Digaetano
    16.00 - 16.30 Discussion and conclusions
  • Ginevra Hall
    14.00-16.30

    Pre-Conference advanced course

    Nurse management of patients with comorbidities

    Pre-Conference advanced course

    Nurse management of patients with comorbidities

    Achieving an undetectable viral load is no longer the sole endpoint in treating HIV. Today's challenge is to guide patients towards a proactive management of HIV-associated comorbidities.  Therapies have improved notably: nowadays patients diagnosed with HIV and treated with the latest antiretrovirals have a life expectancy comparable to the general population. A recent study showed that in 2010 patients' mean age was 43.9 years, whereas in 2030 is expected to be 56.6 years, with patients aged over 50 increasing from 28% to 73%.  Nonetheless, there are more challenges to face: aging with HIV puts patients to an increased risk of developing HIV-related illnesses, such as osteoporosis, hepatic, cardiovascular and neurological disease.  It is therefore necessary for the nursing staff to be to able to lead patients to a successful management of their comorbidities through a learning process based on efficient means of communication aimed at patients' empowerment.

    Chairs: E. Bruni, M. Gatti, S. Patrucco

    14.00 - 14.30 Cardiovascular risk factors
    14.30 - 15.00 Nurse management of frail and elderly HIV-positive patients
    M. Gatti
    15.00 - 15.30 Therapeutic Patient Education in subjects with neurocognitive disorders
    G.P. Oliva
    15.30 - 16.00 Nurse management of cancer patients
    A. Meda
    16.00 - 16.30 The nurse's role in managing the risk of infection in HIV-positive patients
    E. Bruni
 
Auditorium
Polissena A Hall
Polissena B Hall
Ginevra Hall
09.00 - 10.00

Auditorium

Keynote Lectures
10.05 - 11.20
11.25 - 12.15
12.15 - 13.00
13.00 - 14.00
14.00 - 14.30
14.30 - 15.00
15.05 - 15.15
15.20 - 16.05
16.10 - 17.25
17.30 - 18.45

Symposium

Virus persistence and host interactions

Satellite Symposium

Fighting multi drug resistance - the right moment, the right drugs

Sponsored Symposium

Streamline ART from the start: the novel approach of 2DR single pill regimen dolutegravir/lamivudine
 

Sponsored Symposium

POP ART (population on ART): from patient to personas A new approach to fulfill PLHIV expectations

Satellite Symposium

Committed globally to fight HIV and other severe infections

Symposium

New metabolic challenges in comorbidities

Symposium

Lights and shadows in HIV clinical research

Symposium

HIV and Coinfections: new challenges for 2020

Oral Communications

Social Science

Symposium

Challenges in PrEP implementation and TasP confidence
 

Oral Communications

HIV Prevention

Symposium

Proud to be women, proud to fight HIV

Oral Communications

Antiretroviral Therapy

Oral Communications

Clinical Hepatitis and Coinfections

Oral Communications

Pharmacology

Expert Meeting

Recent advances in the management of Gram positive infections: the evolving role of long acting therapy

Expert Meeting

Hepatitis C Elimination: the winning challenge of the 8-weeks treatment

Expert Meeting

Urgent global challenges in infectious diseases: fight together against HIV and AMR

Oral Communications

Comorbidities
 
Meet the Expert
18.45 - 19.30

Auditorium

ICAR-CROI Awards 2020 for young Italian HIV investigators
 
Poster Area
13.00 - 14.30

Poster Discussion

Antiretroviral Therapy

Poster Discussion

Clinical HIV

Poster Discussion

Hepatitis and Coinfections

Poster Discussion

Virology and Pharmacology
 
  • Auditorium
    09.00-10.00 Keynote Lectures

    Keynote Lectures

    Chairs: A. De Rossi, M. Farinella, M. Galli

    09.00 - 09.30 Visions of ART
    A. Pozniak
    09.30 - 10.00 Genomics and proteomics approaches for studies of HIV eradication
    M. Lichterfeld
    10.05-11.20

    Symposium

    Virus persistence and host interactions

    Symposium

    Virus persistence and host interactions

    Antiretroviral therapy (ART) has gained a great deal of success in recent years and succeeded in suppressing viral replication in people infected with HIV. Nevertheless, infected cells persist for decades on ART and HIV-RNA comes back if ART is stopped. Persistence has been attributed to viral replication in cellular/anatomical reservoirs and long-lived and/or proliferating latently infected cells. This symposium aims at shedding light on the fine mechanisms of persistence of retroviruses and their cross-talk with the host immune system.

    Chairs: G. Antonelli, P. Bagnarelli, S. Rusconi

    10.05 - 10.20 Restriction factors and the peculiar function of CIITA
    R. Accolla
    10.20 - 10.35 The persistence of memory: HIV reservoir and adaptive immunity
    F.R. Simonetti
    10.35 - 10.50 Gene editing: from the virus side
    M. Pistello
    10.50 - 11.05 Gene editing: from the cell side
    R. Bella
    11.05 - 11.20 Discussion on Symposium issues
    11.25-12.10

    Satellite Symposium

    Fighting multi drug resistance - the right moment, the right drugs

    Satellite Symposium

    Fighting multi drug resistance - the right moment, the right drugs

    Patients with Multi Drug Resistant (MDR) HIV infection and few residual antiretroviral options are very likely to experience progression of the disease and death. To address this important unmet need, new antiretroviral agents are needed with novel mechanisms of action, good safety profile, no drug-drug interactions and no cross-resistance to other HIV drugs. The Symposium will focus on new modes of action currently in development and share latest clinical data conducted so far with ibalizumab, a new humanized IgG4 monoclonal antibody which blocks the entry of HIV by non-competitive binding to CD4. The Italian experience with the use of ibalizumab will also be presented.

    Chairs: C. Mussini, M. Zazzi

    11.25 - 11.35 New treatments, new options
    A. Antinori
    11.35 - 11.45 Resistance to Long-Acting Antivirals
    C.F. Perno
    11.45 - 11.55 The Italian experience
    A. Castagna
    11.55 - 12.10 Building a fully suppressive regimen for patients with MDR - lessons learned
    B. Emu
    12.15-13.00

    Sponsored Symposium

    Streamline ART from the start: the novel approach of 2DR single pill regimen dolutegravir/lamivudine

    Sponsored Symposium

    Streamline ART from the start: the novel approach of 2DR single pill regimen dolutegravir/lamivudine

    Remarkable advances in drug development for the treatment of HIV-1 infection have been achieved in recent years. From the co-formulation of combination antiretroviral therapy (cART) into single-tablet regimens to the development new antiretroviral drugs, the treatment of HIV has and will become much more tolerable and less complicated for people living with HIV (PLWH). Moreover, there is a focus on reducing short- and long-term toxicities of treatment while maintaining robust efficacy and good tolerability. In this scenario, one of the most recently options considered is 2-drug regimen (2DR) containing highly effective ARV compounds while excluding components that have relatively unfavorable toxicity profiles, with the potential additional advantage to minimize antiretroviral medication burden for improving effectiveness. In this novel therapeutic context, the 2DR consisting of the INSTI dolutegravir (DTG) and the NRTI lamivudine (3TC), represents today the unique regimen extensively studied versus standard 3- or 4-drug regimens both in naïve and virologically suppressed patients. Aim of the symposium is to highlight important considerations for the use of 2DR single tablet DTG/3TC in the context of existing and emerging ARV options.

    Chair: G. Rizzardini

    12.15 - 12.30 The robustness of the evidences up to date: challenging the use of 3 drug regimens
    A. Antinori
    12.30 - 12.45 How dolutegravir/lamivudine meets the patient needs
    F. Maggiolo
    12.45 - 13.00 Discussion on Symposium issues
    14.30-15.15

    Sponsored Symposium

    POP ART (population on ART): from patient to personas A new approach to fulfill PLHIV expectations

    Sponsored Symposium

    POP ART (population on ART): from patient to personas A new approach to fulfill PLHIV expectations

    The advent of the new antiretroviral drugs has permitted to obtain virological success in the majority of treated patients. This achievement has allowed the clinicians to focus on HRQoL (4th 90) to guarantee a long-term well-being. In this new context, populations defined by clinical conditions are now obsolete:  to achieve the 4th 90 goal we need to consider PLHIV lifestyles by moving from patient profile to personas concept. Each personas is different and has different expectations, therefore is crucial to contemplate all the key factors that contribute to obtain a better quality of life. In this evolving scenario, therapy still has a critical role in controlling the virus, but how can it fulfill doctors' and patients' needs to reach the HRQoL (4th 90)?

    Chairs: A. d'Arminio Monforte, C.F. Perno

    14.30 - 15.00 PLHIV in 2020: interactive discussion on personas
    C. Gervasoni, G. Madeddu
    15.00 - 15.15 How therapy can meet patients' needs
    S. Bonora
    15.20-16.05

    Satellite Symposium

    Committed globally to fight HIV and other severe infections

    Satellite Symposium

    Committed globally to fight HIV and other severe infections

    Since the introduction of cART there has been increased survival in HIV-infected persons, so nowadays it is important to answer to individual HIV patients needs, going beyond viral suppression, as antiretroviral therapy is a life-long commitment. Furthermore, with the availability of two or three drugs combinations is becoming more crucial the physician's role in choosing and adapting the ART to treat population living with HIV (PLWH) avoiding issues about adherence, potential drug-drug interactions, long-term toxicities given that the PLWH is ageing with increasing comorbidities such as osteoporosis, renal, cardiovascular, metabolic and liver diseases, which need additional drugs. The aim of the symposium is to examine how current antiretroviral agents may be better incorporated into management strategies in daily practice to benefit patient's individuality now and to preserve the future. In this changing scenario, is interesting to show how the well-known NNRTI rilpivirine (RPV) has remained central to several key therapeutic innovations due to its proven durable efficacy & tolerability that delivers multiple benefits for HIV patients. Furthermore, while the global genetic diversity of HIV poses a considerable scientific challenge, the symposium will be an opportunity to discuss on the lnfectivologists & pharma company's commitment to HIV and other infections vaccine research, aiming to address these problems.

    Chair: C. Mussini

    15.20 - 15.35 Indhividuality: beyond viral suppression
    G. Madeddu
    15.35 - 15.50 The rilpivirine perspective: present and future
    S. Lo Caputo
    15.50 - 16.05 Back to basic: paving the way to HIV and other infections vaccines
    A. Castagna
    16.10-17.25

    Symposium

    New metabolic challenges in comorbidities

    Symposium

    New metabolic challenges in comorbidities

    HIV ad cART comorbidities are continuously changing their presentations, in parallel with the evolving spectrum of antiretroviral treatment regimens and the demographic and clinical features of people with HIV (PWH). At present, the current scenario of metabolic comorbidities seems to reflect, on one hand, the extended use of potent antiretroviral drugs with a very high safety profile, and, on another hand, the increasing age of PWH and the persisting immune activation. This symposium discusses emerging issues in the field, including prevalence and impact of these complications and explore the potential of old and new tools for their definition and management.

    Chairs: A. Bandera, P. Bonfanti, F. Castelli

    16.10 - 16.25 The growing burden of nonalcoholic fatty liver disease in people aging with HIV
    G. Sebastiani
    16.25 - 16.40 Weight gain and new antiretrovirals: is a real issue?
    S. Cicalini
    16.40 - 16.55 Immune-metabolic interventions as geroprotective agents in HIV
    G. Guaraldi
    16.55 - 17.10 Artificial intelligence in aging: from data collection to data analitics
    C. Grana
    17.10 - 17.25 Discussion on Symposium issues
    17.30-18.45

    Symposium

    Lights and shadows in HIV clinical research

    Symposium

    Lights and shadows in HIV clinical research

    Evidence based medicine relies on well conducted clinical trials and comprehensive cohort data to draw its indications. However, no experimental design is completely free of drawbacks and limitations. Therefore, the results of different clinical experiences must be read in a critical way understanding which is the right field of application. The problem is further complicated in a constantly expanding field as HIV/AIDS by the need to adequate outcomes and measures to newly defined goals. The symposium will offer a comprehensive discussion about all these critical aspects of clinical management of HIV/AIDS.

    Chairs: P.M. Cinque, N. Gianotti, A. Gori

    17.30 - 17.45 What trials did not show
    F. Maggiolo
    17.45 - 18.00 What we cannot expect from clinical cohorts
    A. Cozzi-Lepri
    18.00 - 18.15 Innovative outcomes: what surrogate outcomes
    M. Santoro
    18.15 - 18.30 Unconventional innovative outcomes
    A. Cingolani
    18.30 - 18.45 Discussion on Symposium issues
    18.45-19.30 ICAR-CROI Awards 2020 for young Italian HIV investigators
  • Polissena A Hall
    10.05-11.35

    Symposium

    HIV and Coinfections: new challenges for 2020

    Symposium

    HIV and Coinfections: new challenges for 2020

    In the last years the control of HIV replication  obtained excellent results with more than 90% of patients being undetectable. However, clinical challenges in the management of HIV infected patients still remain, such as the presence of co-infections with viruses such as HBV and HPV, both involved in cancer development, as well as with tuberculosis. The symposium will focus on such pathogens, discussing the challenges in terms of clinical history, diagnosis and treatment.

    Chairs: R. Bruno, M. Stagnitta, G. Taliani

    10.05 - 10.20 Critical epidemiological and virological insights on HBV coinfection
    V. Svicher
    10.20 - 10.35 HBV: from new drugs to functional cure
    M. Puoti
    10.35 - 10.50 HPV-associated ano-genital lesions in HIV patients
    M. Giuliani
    10.50 - 11.05 HPV-driven oropharyngeal cancer in the HIV/AIDS patient
    P. Boscolo Rizzo
    11.05 - 11.20 Which is the best approach to screen HIV-infected individuals for latent tuberculosis infection in Italy?
    D. Goletti
    11.20 - 11.35 Discussion on Symposium issues
    11.40-12.55

    Oral Communications

    Social Science

    Oral Communications

    Social Science

    Chairs: G. Liuzzi, A. Matteelli, L.A.R. Rancilio

      125Awareness and perception of accuracy of the U = U message in people living with HIV (PLWHIV), in Italy and correlation with the level of confidence in reference physicians
    A. Cingolani,
      341Hepatitis C, HIV and Tubercolosis among vulnerable populations in an out-of-hospital setting: a seroprevalence analysis from The week of the poor experience
    G. De Simone,
      42Engagement of younger generations in the fight against HIV/AIDS
    P. Meli,
      238Post-migration HIV infection in the foreign-born population enrolled in the ICONA cohort
    A. Saracino,
      256BLQ Checkpoint: characteristics of users and services offered. A 5 years review
    G.M. Corbelli,
      293Sexual behaviour and associated risk for sexual health among men who have sex with men (MSM) in Italy: data from the EMIS 2017 survey
    M. Breveglieri,
    13.00-14.00

    Symposium

    Challenges in PrEP implementation and TasP confidence

    Symposium

    Challenges in PrEP implementation and TasP confidence

    Pre-exposure prophylaxis (PreP) for HIV has proven effective in reducing the number of new infections in several trials and in different settings, while treatment as prevention (TasP) is one of the major advancements in the HIV field, becoming a major argument for supporting both the universal treatment and test and treatment strategies. However, issues are arising in PreP implementation in clinical practice, while the trust in TasP may be challenging when it comes to the real world, as both patients and clinicians may have different interpretations, expectations and confidence.

    Chairs: D. Ripamonti, L. Sighinolfi, P. Tomasi

    13.00 - 13.15 PrEParing providers
    S. Venturelli
    13.15 - 13.30 Challenges in becoming a PrEP user
    A. Infante
    13.30 - 13.45 How much trust in TasP?
    S. Venturelli
    13.45 - 14.00 Consequences of TasP
    A. Infante
    16.10-17.25

    Oral Communications

    HIV Prevention

    Oral Communications

    HIV Prevention

    Chairs: A. Bignardi, T.S. Prestileo, B. Suligoi

      308Engagement, adherence and rate of discontinuation in an Italian access program of HIV pre-exposure prophylaxis (ItaPrEP)
    V. Mazzotta,
      299Pre-Exposure Prophylaxis (PrEP) use at five Infectious Diseases Units in northern Italy (PrEP-Italy study)
    S. Venturelli,
      345Uptake and effects on sexual behaviour in a cohort of PrEP users
    P.L.G. Vinti,
      349Preventive measures against HIV and sexually transmitted infections among key populations referring to a counseling and testing center in the metropolitan area of Rome
    R. Esvan,
      269Incidence of STIs and HIV in a cohort of MSM and MtF with high prevalence of risk factors for HIV acquisition evaluated in a PrEP community-based service in Italy: one-year follow-up data from SEX-CHECK study
    D. Testi,
      221HIV and motherhood - A survey on women's experiences in the U=U era
    M.G. Di Benedetto,
    17.30-18.45

    Symposium

    Proud to be women, proud to fight HIV

    Symposium

    Proud to be women, proud to fight HIV

    The efforts made so far in terms of controlling the HIV epidemic on a global level have left women behind compared to the achievement of the objectives set by the WHO. This is because a tailored approach specifically aimed at the female population is far from being applied both in terms of implementation of prevention tools and of clinical and psychological management of women. The objective of this symposium is to focus attention and reflect on peculiar aspects of women's health to ensure that this gap is quickly bridged.

    Chairs: G. Lapadula, A. Moznich, G. Scarlatti

    17.30 - 17.45 Gender differences in HIV bio-medical prevention
    S. Strachan
    17.45 - 18.00 Gender gaps in Italian cascade-of-care
    M. Errico
    18.00 - 18.15 Women well-being and safe childbearing: updated management strategies
    F. Sabbatini
    18.15 - 18.30 Women are from Venus - Implications for prevention and cure
    G.C. Marchetti
    18.30 - 18.45 Discussion on Symposium issues
  • Polissena B Hall
    10.05-11.20

    Oral Communications

    Antiretroviral Therapy

    Oral Communications

    Antiretroviral Therapy

    Chairs: M. Malena, C. Torti

      122Durability of dolutegravir-based regimens after the first year of therapy
    L. Taramasso,
      39Switch to RPV+DRV/cobi: 48week results of the PROBE 2 study
    F. Maggiolo,
      131Predictors of virological failure among HIV-1 infected patients switching from an effective first line antiretroviral regimen. A preliminary analysis
    L. Magnasco,
      38Long term efficacy of dolutegravir + lamivudine as simplification cART in patients with suppressed HIV-RNA
    F. Maggiolo,
      109Lamivudine+dolutegravir (3TC+DTG) switch strategy compared with the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppressed HIV patients: preliminary results from an Italian center
    G. Baldin,
      283Durability of F/TAF regimens in the era of integrase inhibitors in a large cohort of PLWH seen for care in Italy
    A. Vergori,
    11.25-12.40

    Oral Communications

    Clinical Hepatitis and Coinfections

    Oral Communications

    Clinical Hepatitis and Coinfections

    Chairs: G. Mazzola, T.A. Santantonio

      229The contribution of late presentation and late ART initiation to TB-HIV occurrence across four countries
    E. Girardi,
      66HPV 16 and 18 infections contribute to development of anal cytological abnormalities in a cohort of PLWH
    N. Squillace,
      213Impact of syphilis on the risk of HIV viral rebound in HIV positive patients under effective antiretroviral treatment: data from the ICONA cohort
    A. Giacomelli,
      300Decrease of prevalence of subjects harboring replicating HCV among PLWHIV in Italy: results from the NoCo study
    A. d'Arminio Monforte,
      164Innovative procedures for micro-elimination of HCV infection in a high-risk population of undocumented migrants and low-income refugees
    M. Macera,
      307HCV treatment and reinfection risk in injecting drug users in Residential Treatment Setting for drug addiction. San Patrignano HCV-free
    P. Piselli,
    12.45-14.00

    Oral Communications

    Pharmacology

    Oral Communications

    Pharmacology

    Chairs: S. Bonora, C. Gervasoni

    12.45 - 13.00 The importance of deprescribing in HIV
    J. Moltò
      75Use of direct oral anticoagulants in people living with HIV: a single-center experience
    C. Gervasoni,
      2Pharmacokinetics of once-daily doravirine over 72 hours following drug cessation
    M. Mazzitelli,
      241Inflammation Affects Antiretrovirals Plasma and Intracellular Exposure
    M. Ferrara,
      255Bictegravir plasma and intracellular pharmacokinetics in in the clinical setting
    M. Ferrara,
      171Generic pre-exposure prophylaxis formulations: a comparison of tenofovir trough concentrations
    D. Cattaneo,
    14.00-15.00

    Expert Meeting

    Recent advances in the management of Gram positive infections: the evolving role of long acting therapy

    Expert Meeting

    Recent advances in the management of Gram positive infections: the evolving role of long acting therapy

    Gram positive infections are a continuing challenge for clinicians: while classic pathogens still persist and evolve acquiring new mechanisms of resistance, new pathogens emerge with intrinsic multiple antibiotics resistance profiles, causing life-threatening infections as nosocomial pneumonia and intravascular device associated bloodstream infections. Not less important, the population at risk, i.e. elderly with multiple comorbidities or recipients of various foreign bodies, is increasing. New therapy options are required, with increased bactericidal activity and antibacterial spectrum that includes multiple resistant pathogens. Recently, the antimicrobial armamentarium has been enriched by a lipoglycopeptide with a very prolonged half-life (dalbavancin) enabling treatment with a single intravenous administration.  Pharmacokinetic profile and convenient single dosing make dalbavancin an interesting option for other serious Gram positive infections requiring prolonged treatment courses, for example bone infections, endocarditis and intravascular line associated infections. The aim of this workshop is to focus on new pharmacological, clinical and pharmacoeconomical data with dalbavancin in order to provide an up-to-date of the actual and potential future role of this options for serious Gram positive infections.

    Chair: M. Tavio

    14.00 - 14.15 Gram+ subacute infections
    P. Viale
    14.15 - 14.30 The evolving role of long acting therapy in the management of Gram positive infections
    M. Andreoni
    14.30 - 14.45 Dalbavancin: pharmacokinetical data
    P. Viale
    14.45 - 15.00 Dalbavancin: pharmacoeconomical data
    M. Andreoni
    15.05-16.05

    Expert Meeting

    Hepatitis C Elimination: the winning challenge of the 8-weeks treatment

    Expert Meeting

    Hepatitis C Elimination: the winning challenge of the 8-weeks treatment

    Thanks to the DAAs, the WHO's goal of HCV elimination by 2030 could be achieved more easily. The high efficacy of these antiviral drugs, characterized by great power, few DDIs and short treatment make the patient's journey less onerous and heavy. Clinical trials and RWE data demonstrate not only the high SVR rate of the short therapies but also the improvement of adherence to the treatment. This last aspect is fundamental for the special populations (PWIDs and patients from SERD) because the briefer the therapy, the less burdensome it is for them. The Expert Meeting will focus precisely of the opportunity of the short therapy in the challenge against HCV. In this context, it represents an important step towards the efforts for eliminating the hepatitis C because it evaluates a brief antiviral regimen in untreated patients without cirrhosis and with compensated cirrhosis, across HCV genotypes 1-6. Through a talk show session, the two Professors will explain and convey the main data and results of this HCV turning point to the audience. The latter will be able to intervene in the session thanks to an interactive platform that will allow the physicians to answer the questions formulated by the speakers.

    15.05 - 16.05 Hepatitis C Elimination: the winning challenge of the 8-weeks treatment
    M. Andreoni, M. Puoti
    16.10-17.10

    Expert Meeting

    Urgent global challenges in infectious diseases: fight together against HIV and AMR

    Expert Meeting

    Urgent global challenges in infectious diseases: fight together against HIV and AMR

    The objective of this expert meeting is to give an update on the current global health challenges in infectious diseases, giving a clear picture on how HIV and AMR are impacting our country and patients' life. Prevention and protection of future generations is becoming increasingly important in HIV: awareness, innovative drugs and quality of life are essential to ensure the achievement of Global UNAIDS objectives. Together with HIV, the fight against drug resistance is a priority at worldwide level with Antimicrobial resistance (AMR) as the most important infectious disease threat of our time. The impact of AMR on patients' life creates the need to accelerate the fight in hospital setting and to ensure the dissemination of strategies and tools for an appropriate management.

    Chair: G. Di Perri

    16.10 - 16.20 Introduction
    16.20 - 16.40 Objective: Future HIV free generations
    A. Antinori
    16.40 - 17.00 AMR: impact on patients' life and strategies for an appropriate management
    P. Viale
    17.00 - 17.10 Discussion on Expert Meeting issues
    17.30-18.45

    Oral Communications

    Comorbidities

    Oral Communications

    Comorbidities

    Chairs: D. Francisci, G. Parruti

      296Fat distribution and density in PLWH with >=5% weight gain
    M. Menozzi,
      1Statin Eligibility in People living with HIV: are we using the right tools to identify patients at risk of developing major cardiovascular disease?
    M. Mazzitelli,
      93Prevalence, predictors and evolution of lean non-alcoholic fatty liver disease in HIV mono-infected patients
    A. Cervo,
      355NAFLD with significant fibrosis in PLWH informs the natural history of cardiovascular disease
    J. Milic,
      26Decline of metabolic syndrome and increase in overweight in HIV infected patients from 2005-2015
    G. De Socio,
      328Progression of anal/cervical dysplasia is associated with Human Papillomavirus (HPV) and Syphilis coinfection in HIV-infected patients
    C. Tincati,
  • Ginevra Hall
    13.00-14.30

    Special event

    Meet the Expert

    Meet the Expert

    During these Sessions, participants will have the opportunity to informally discuss with top ICAR Experts and exchange with them personal views, receive practical insights about specific topics. Guided by Facilitators, these sessions represent an important opportunity for all delegates to sit down and converse on a more one-to-one level.

    Chairs: M. Breveglieri, S. Mattioli

    13.00 - 13.30 Antiretroviral therapy
    A. Pozniak
    13.30 - 14.00 Cure
    F.R. Simonetti
    14.00 - 14.30 Transgender
    O. Voza
  • Poster Area
    13.00-14.30

    Poster Discussion

    Antiretroviral Therapy

    Poster Discussion

    Antiretroviral Therapy

    Chairs: R. Maserati, P. Nasta

      188Evaluation of total HIV-DNA and residual viremia in HIV-1 infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-OnE Study
    M. Santoro,
      268Durability and liver safety of InSTI-based regimens in HIV-infected patients with advanced liver fibrosis or cirrhosis: data from the ODOACRE cohort
    A. Lanari,
      281Prevalence of transmitted resistance mutations to rilpivirine and doravirine in treatment-naive patients in a large clinical and resistance database
    F. Lombardi,
      117Efficacy and tolerability of bictegravir/ tenofovir alafenamide/ emtricitabine as a switch strategy in a cohort of antiretroviral therapy treatment-experienced HIV-1-infected patients
    F. Lagi,
      163Viral rebound in pts with suppressed HIV-RNA on a 2 or 3-drug regimen: a comparison
    A. Borghetti,
      191Optically traceable PLGA Nanoparticles improve the ability of darunavir to cross the blood brain barrier and inhibit MMP-9. Implications for the Treatment of HIV-Associated Neurological Disorders
    S. Milella,
      199Effectiveness and long-term durability of rilpivirine-based single tablet regimens in a large cohort of HIV-infected patients. A preliminary analysis
    R. Pincino,
      5INCREASE iN BODY WEIGHT AFTER A YEAR OF INI-EXPOSURE IN A MULTICENTER ITALIAN COHORT
    A. Ciccullo,
      226Treatment outcome among HIV-1 infected patients who started first-line ART pending GRT results from 2015 to 2018
    D.F. Bavaro,
      92Retrospective analysis of reasons and characteristics of switches in a cohort of women affected by HIV infection referring to D. Cotugno Hospital, Naples, period 2017-2019
    F.M. Fusco,
      217Assessing the feasibility of 2-drug regimens as switch strategies in a multicenter cohort
    A. Ciccullo,
      95Risk of failure in dual vs triple therapy in naïve HIV-patients: a meta-analysis
    A. Russo,
    13.00-14.30

    Poster Discussion

    Clinical HIV

    Poster Discussion

    Clinical HIV

    Chairs: M. Borderi, A. Ruggieri

      276Newly diagnosed HIV infected patients in Brescia, Northern Italy: epidemiological and clinical characteristics and possible targets of prevention and early diagnosis campaign
    G. Zuglian,
      16Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in HIV-infected patients with metabolic syndrome
    L. Calza,
      275Durability of InSTI-based regimen in geriatric people living with HIV. Data from the Italian Multicenter GEPPO Cohort
    E. Focà,
      206Weight gain and body composition changes in people living with HIV treated with Integrase Strand Transfer Inhibitors: a longitudinal assessment with Bioimpedance Vectorial Analysis
    M. Poliseno,
      189Transmitted drug resistance in newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy
    L. Calza,
      28Same day treatment and rapid antiretroviral therapy introduction in a cohort of unselected newly-diagnosed HIV-positive individuals
    G. Lapadula,
      250Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression
    C. Muccini,
      59A descriptive analysis on dual regimens' discontinuations in a multicentre Italian cohort
    D. Farinacci,
      346Virological response and resistance profile in highly treatment-experienced HIV-1 infected patients switching to dolutegravir plus boosted-darunavir in clinical practice
    D. Armenia,
      295Does rapid initiation of ART at HIV diagnosis impact on virological response and retention in care? A single center experience (Brescia, Northern Italy)
    A. Comelli,
      264Efficacy and durability of dolutegravir- or darunavir-based regimens in ART-naïve AIDS- or late-presenter patients
    M. Masini,
      259Efficacy Safety and Tolerability of the switch from efavirenz/emtricitabine/tenofovir disoproxil on alternate days or continuous treatment to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV+ (EBONY Study)
    M. Camici,
    13.00-14.30

    Poster Discussion

    Hepatitis and Coinfections

    Poster Discussion

    Hepatitis and Coinfections

    Chairs: O. Armignacco, M. Massari, C. Sagnelli

      179Rapid Detection of Mycobacterium tuberculosis DNA in pulmonary and extrapulmonary paraffinized samples by ddPCR
    M. Antonello,
      153Pharyngeal contamination is a major driver for sexually transmitted infections epidemic in Men who have Sex with Men
    R. Rossotti,
      97HCV infection in PWUD: a microelimination intervention in Rome
    C. Taibi,
      98Direct-acting antiviral based treatment for HCV-infected persons who inject drugs: a multi-centre real-life study
    L. Onorato,
      322Are Non-Injecting Drug Users at risk of HCV-infection? Data from the San Patrignano cohort
    A. Boschini,
      187Real Life DAAs in a large cohort of people who use drugs with hepatitis C virus infection in Tor Vergata Hospital in Rome: adherence, efficacy and reinfections of a key population
    T. Mulas,
      342Effects of HCV eradication on liver function in haemophilic HIV/HCV co-infected patients
    V. Castelli,
      248Virological patterns of HCV-patients with failure to second generation direct-acting antivirals
    M. Starace,
      47Advanced liver disease outcomes after Hepatitis C viral eradication according to Human Immunodeficiency Virus coinfection in PITER cohort
    M.G. Quaranta,
      312The combination of accurate serological and virological HBV markers can help to predict the occurrence of HBV reactivation and to optimize prophylaxis duration in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases
    M. Alkhatib,
      134HBV and HDV infection in immigrants living in South Italy: epidemiological and virological characteristics
    L. Onorato,
      130HEV infection as an emergent public health issue: is it a concern for Italian blood donors?
    L. Colagrossi,
    13.00-14.30

    Poster Discussion

    Virology and Pharmacology

    Poster Discussion

    Virology and Pharmacology

    Chairs: R. Cavallo, S. Parisi

      271The HIV-1 provirus excised by CRISPR/Cas9 may be integrated back into the cell genome in presence of the viral integrase
    M. Lai,
      192Analysis of HIV latency establishment and maintenance in CD4 T cells stimulated with IL-15
    L. Manganaro,
      76Phylogenetic analyses applied to the study of transmission variants and their evolution in a HIV-1 positive couple
    C. Fenizia,
      74Creation of an Italian HIV DNA Network for the validation and clinical use of HIV-1 DNA quantification assays
    I. Vicenti,
      63Initial characterization of elements detected and quantified exclusively on the basis of LTR region by Aptima HIV-1 Quant Dx dual-target assay in plasma of HIV-positive patients
    A. Amendola,
      208Stable total HIV-DNA after 1 year on switch to TAF-based regimens in real world data
    C. Alteri,
      165HIV-1 RNA and DNA mutational load in HTE patients with MDR virus: a tool for deciding OBR?
    D. Armenia,
      96Viral tropism does not have any impact on CD4 recovery in acute HIV infection or AIDS
    D. Vita,
      291Antiviral effect of HIV1 tat/rev siRNA carried by nanoparticles in human CD4+ T cell line
    F. Falasca,
      344A real-life experience of vaccination strategies for HBV prevention in HIV patients
    D. Tomasoni,
      235A successful experience of an immunization program in HIV-positive adults
    G. Chieffo,
      64Plasma exchange and dolutegravir exposure. A case report
    M. Mussa,
 
Auditorium
Polissena A Hall
Polissena B Hall
Ginevra Hall
09.00 - 10.00

Auditorium

Keynote Lectures
10.05 - 11.20
11.25 - 12.10
12.15 - 13.30
13.35 - 14.50

Symposium

Reaching out: same models for different infections

Satellite Symposium

HIV: understanding the real burdens of the disease
 

Symposium

The Fast-Track Cities initiative and the Italian state of the art

Symposium

Immune control over HIV reservoir

Oral Communications

Immunopathogenesis

Symposium

ART treatment: when the patient's journey becomes difficult

Oral Communications

Virology

Expert Meeting

Enhancing care for people living with HIV: current and future of monitoring approaches

Oral Communications

Hepatitis and Clinical Virology
Special Session on HIV and COVID in Italy

Oral Communications

Clinical HIV
 

Oral Communications

Social Science and Epidemiology
Meet the Expert

Oral Communications

Basic Science and Immunology
14.55 - 15.55

Auditorium

Round Table: HIV in COVID-19 era: how to ensure quality of care and outpatient management
16.00 - 16.30

Auditorium

ICAR 2020 Special Awards
16.30 - 16.45

Auditorium

ICAR 2020 Closing remarks
 
Poster Area
12.15 - 13.30

Poster Discussion

Clinical HIV II

Poster Discussion

Comorbidities

Poster Discussion

Basic Science and Immunology

Poster Discussion

Social Science and Prevention
 
  • Auditorium
    09.00-10.00 Keynote Lectures

    Keynote Lectures

    Chairs: S. Di Giambenedetto, E. Girardi, F. von Schloesser

    09.00 - 09.30 Orientating in a maze. The Arianna's thread to partner notification
    M.L. Cosmaro
    09.30 - 10.00 New challenges in virology: SARS-CoV-2
    M.R. Capobianchi
    10.05-11.20

    Symposium

    Reaching out: same models for different infections

    Symposium

    Reaching out: same models for different infections

    The first of the United Nations' 90-90-90 targets to end the HIV epidemic is for 90% of people living with HIV to learn their HIV status. HIV testing is therefore essential to achieving the first 90. The only way to determine a person's HIV status is for them to have an HIV test. What is the best way? HIV testing in healthcare services is the traditional approach. Good results have been accomplished through it but there are some obstacles as  limited access and usability of the healthcare structures and the difficulty of people to undergo the test in the hospital. In recent years, the Point of Care (POC) have been successful to overcome some difficulties and to make easier the access to the test especially for populations who showed reluctance to go to the hospital. The European POC has also created a network to facilitate access to the hospital and to make access to care simpler and faster. It already has the result to accelerate the United Nations' 90-90-90 campaign . Discussing and finding further solutions requires reflection on the experiences that have been carried out by NGOs. Looking for concrete collaborations and new intervention strategies between POC and hospital can bring us closer to the WHO objectives and reinforce the equation Undetectable = Untransmittable (U=U) message. There is an opportunity to improve prevention, testing services and ensure high-quality well-adhered treatment and care for all.

    Chairs: B. Marchini, V. Puro, E. Vaccher

    10.05 - 10.20 Amending missed opportunities for HIV testing in healthcare services
    S. Nozza
    10.20 - 10.35 Testing, prevention and treatment outside of the hospital: the checkpoint model
    G.M. Corbelli
    10.35 - 10.50 We are not hard to reach - Bringing people to the hospital and vice versa
    E. Teti
    10.50 - 11.05 Integrated health policies: barriers, challenges and opportunities
    L. Rizzo Nervo
    11.05 - 11.20 Discussion on Symposium issues
    11.25-12.10

    Satellite Symposium

    HIV: understanding the real burdens of the disease

    Satellite Symposium

    HIV: understanding the real burdens of the disease

    The today new standards of highly virologically effective antiretroviral regimens fully authorize clinicians to move the attention from pursuing viro-immunological outcomes, namely efficacy, to also considering in the clinical practice concrete strategies for preserving both quality of life and long-term well-being, namely effectiveness. Reducing all kind of medication burdens, both pharmacological and taking medicine ones, suggest a patient-centered approach.

    Chair: C. Mussini

    11.25 - 11.40 Reducing ARV and taking medicines burdens for improving effectiveness
    M. Andreoni
    11.40 - 11.55 The evaluation of patient complexity in the setting of ARV deprescribing
    G. Guaraldi
    11.55 - 12.05 Discussion on Symposium issues
    12.05 - 12.10 Closing remarks
    C. Mussini
    13.35-14.50

    Symposium

    The Fast-Track Cities initiative and the Italian state of the art

    Symposium

    The Fast-Track Cities initiative and the Italian state of the art

    The Fast-Track Cities initiative is a global partnership between cities and municipalities around the world and four core partners - the International Association of Providers of AIDS Care (IAPAC), the Joint United Nations Programme on HIV/AIDS (UNAIDS), the United Nations Human Settlements Programme (UN-Habitat), and the City of Paris. Launched on World AIDS Day 2014, the network has grown to include more than 300 cities and municipalities that are committed to attain the UNAIDS 90-90-90 targets by 2020. The aim of the symposium is to discuss the global initiatives and to focus on the Italian Fast-Track Cities state of the art, in a round table involving the different Italian Fast-Track Cities' stakeholders.

    Chair: B. Audoin

    Discussants: A. d'Arminio Monforte, M.R. Iardino

    13.35 - 13.45 Introduction
    B. Audoin
    13.45 - 14.00 The Global Network
    R.B. Leite
    14.00 - 14.50 Round Table "The Italian Fast-Track Cities"
    Participants: A. Cascio, G. Cenderello, A. Di Biagio, M. Di Pietro, F. Vichi, F. Maggiolo, D. Maineri
    14.55-15.55 Round Table: HIV in COVID-19 era: how to ensure quality of care and outpatient management

    Round Table

    HIV in COVID-19 era: how to ensure quality of care and outpatient management

    2020 has been so far very challenging for infectious disease specialists around the world especially for new coronavirus. The aim of the round table is to discuss how this emergency impacted on the outpatient management of HIV infected patients and, more generally, on their quality of care. Clinicians will talk about clinic experiences, recommendations and organizational models on management and security, diagnosis, screening, telemedicine while patients will relate about their perception on the quality of care with a focus on PrEP and STI management.

    Chairs: M. Andreoni, A.M. Cattelan

    Participants: M.G. Di Benedetto, M. Lichtner, S. Mattioli, S. Rusconi
    16.45-17.00 ICAR 2020 Special Awards

    ICAR 2020 Special Awards

    Chairs: M. Clementi, S. Mattioli, C. Mussini, G. Silvestri, M. Tavio

    17.00 - 17.15 ICAR 2020 Closing Remarks

    Closing remarks

    Chairs: M. Clementi, S. Mattioli, C. Mussini, G. Silvestri, M. Tavio

  • Polissena A Hall
    10.05-11.20

    Symposium

    Immune control over HIV reservoir

    Symposium

    Immune control over HIV reservoir

    Despite full control over HIV replication by cART, HIV has been shown to persist in lymphoid tissues, and represent a major obstacle to HIV eradication. The symposium will review the major immunologic pathways behind immune control over HIV, alongside the distinguishing features of patients with progressive versus non-progressive disease.

    Chairs: A. Caruso, M.S. Clerici, L. Sarmati

    10.05 - 10.20 Models of natural protection against HIV infection and progression
    M. Biasin
    10.20 - 10.35 Innate immunity: don't forget the macrophages!
    G. Poli
    10.35 - 10.50 Inflammatory stem cells
    A. De Maria
    10.50 - 11.05 Killing HIV by bNABs: apocalypse, now?
    L. Lopalco
    11.05 - 11.20 Discussion on Symposium issues
    11.25-12.10

    Oral Communications

    Immunopathogenesis

    Oral Communications

    Immunopathogenesis

    Chairs: M. Nasi, G. Nunnari

      327Psycosexual health and systemic, mucosal immune activation and in hiv-infected ART suppressed and uninfected women: evaluation of biomarkers and environmental stimuli
    P. Nijhawan,
      182Inflammatory burden in people living with four-class drug resistant HIV: data from the PRESTIGIO registry
    T. Clemente,
      223Gut microbial dysbiosis is linked to immune-reconstitution and CD4+ T-cell skewing in MSM with high Framingham Risk Score
    G. Ancona,
    12.15-13.30

    Symposium

    ART treatment: when the patient's journey becomes difficult

    Symposium

    ART treatment: when the patient's journey becomes difficult

    The high efficacy and tolerability of antiretroviral drugs nowadays available might give the impression that treating HIV infection is today an easy task. That could even be true in a fairly large proportion of patients but, as in every population, ties exist and these extremes of the Gaussian curve are the challenging patients. The symposium will offer a comprehensive overlook on different difficult to treat patients offering hints to an optimized clinical management in these specific situations. When the play gets tough, tough guys start to play.

    Chairs: T. Bini, L. Calza, M. Cernuschi

    12.15 - 12.30 Advanced naives
    A. Mondi
    12.30 - 12.45 Multi-drug resistant
    A. Castagna
    12.45 - 13.00 Fragile-social desparities
    A. Saracino
    13.00 - 13.15 Addressing personal barriers
    M. Oldrini
    13.15 - 13.30 Discussion on Symposium issues
    13.35-14.50

    Oral Communications

    Virology

    Oral Communications

    Virology

    Chairs: S. Menzo, M.C. Re

      99Defining stable reference genes to analyze cell associated HIV RNA induced by latency reversing agents
    C. Ceriani,
      272Prevalence of drug resistance mutations to rilpivirine and doravirine among NNRTI -experienced patients in Italy: a cross-sectional study
    A. Lai,
      251HIV-DNA from rectal GALT is a valid marker to characterize the viral reservoir
    C. Stingone,
      67Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients
    Y. Bouba,
      262Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study
    A. Emiliozzi,
      77Prevalence of high-risk HPV genotypes and HPV genotypes targeted by the nine-valent vaccine Gardasil-9 and the associated risk factors
    E. Bruzzesi,
  • Polissena B Hall
    10.15-11.15

    Expert Meeting

    Enhancing care for people living with HIV: current and future of monitoring approaches

    Expert Meeting

    Enhancing care for people living with HIV: current and future of monitoring approaches

    The most significant advance in the medical management of HIV-1 infection has been the treatment of patients with antiretroviral (ART) drugs, which can suppress HIV-1 replication to undetectable levels. Despite this HIV cannot currently be eradicated from the body, and antiretroviral treatment thus has to be indefinitely maintained. People living with HIV will have to go a long way and only CD4+ lymphocytes count and HIV-RNA load will not be able to adequately inform the doctor and the researcher about the real benefit of the ART. New approaches need to be defined for monitoring people with HIV infection, including clinical, virological, immunological parameters and also the point of view of people living with HIV. The purpose of this Expert Meeting is to highlight the evidence on different biomarkers or innovative approach use in research and clinical settings, to better define the management of HIV infection.

    Chairs: A. Di Biagio, F. Maggiolo

    10.15 - 10.20 Introduction
    F. Maggiolo
    10.20 - 10.30 Virology
    S. Rusconi
    Gruppo di lavoro: N. Gianotti, R. Maserati, S. Rusconi, M. Zazzi
    10.30 - 10.40 Immunology and inflammation
    G.C. Marchetti
    Gruppo di lavoro: A. Bandera, A. Calcagno, M. Lichtner, G. Marchetti
    10.40 - 10.50 Comorbidities
    G. Madeddu
    Gruppo di lavoro: S. Bonora, G. Madeddu, M. Borderi, P. Maggi
    10.50 - 11.00 PROs, Patient-reported outcomes
    A. Cingolani
    Gruppo di lavoro: A.M. Cattelan, A. Cingolani, S. Lo Caputo, S. Nozza
    11.00 - 11.10 Discussion
    11.10 - 11.15 Closing remarks
    A. Di Biagio
    11.25-12.10

    Oral Communications

    Hepatitis and Clinical Virology

    Oral Communications

    Hepatitis and Clinical Virology

    Chairs: N. Coppola, G. Verucchi

      331Unexpected rising in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies
    L. Piermatteo,
      80HCV genetic variability in patients with related hepatocellular carcinoma
    A. Di Fraia,
      334Prevalence and Resistance Analysis of Unusual Hepatitis C Virus (HCV) Subtypes within the Italian Resistance Network VIRONET-C
    V.C. Di Maio,
    12.15-13.30

    Special event

    Special Session on HIV and COVID in Italy

    Special event

    Special Session on HIV and COVID in Italy

    Chairs: G. Angarano, E. Vicenzi

    13.35-14.50

    Oral Communications

    Clinical HIV

    Oral Communications

    Clinical HIV

    Chairs: A. Calcagno, M.C. Moioli

      317Machine learning statistical approach to identify HIV co-infected patients with asymptomatic neurosyphilis
    L. Celani,
      231Body composition changes in HIV: do INSTI matter?
    J. Milic,
      86Risk of weight gain (WG) according to type of switching strategy in a large cohort of HIV-infected individuals with stable suppressed HIV-RNA
    S. Cicalini,
      306Impact of antiretroviral therapy on gut CD4 T cells activation: differences between naïve and long-term treated HIV-1 infected patients
    G.P. Innocenti,
      150Residual Inflammation and CD4/CD8 Recovery After Switching to Dual Therapy
    E. Merlini,
      228Evaluation of the impact of resistance on virological efficacy of STR regimens and emergence of resistance at virological failure
    G. Stella,
  • Ginevra Hall
    10.45-12.00

    Oral Communications

    Social Science and Epidemiology

    Oral Communications

    Social Science and Epidemiology

    Chairs: A. Franco, M. Manfredini, G. Orofino

      311 A less recent diagnosis is associated with local transmission clusters among HIV-1 primary infections in Rome
    L. Fabeni,
      267High HIV Prevalence following Screening of Subjects with HIV Indicator Conditions in a Hospital Setting
    C. Tincati,
      40The cascade of care as tool to promote a more effective city-wide program against HIV/AIDS
    F. Maggiolo,
      25Causes and incidence of hospitalization in patients enrolled in the ICONA cohort
    S. Nozza,
      61The 4th Ninety in the 4th Decade
    A. Bove,
      326General Practitioners and PLWH: what do patients think?
    S.R. Bruno,
    12.00-13.30

    Special event

    Meet the Expert

    Meet the Expert

    During these Sessions, participants will have the opportunity to informally discuss with top ICAR Experts and exchange with them personal views, receive practical insights about specific topics. Guided by Facilitators, these sessions represent an important opportunity for all delegates to sit down and converse on a more one-to-one level.

    Chairs: M. Cascio, S. Mattioli

    12.00 - 12.30 Chemsex
    C. Di Feliciantonio
    12.30 - 13.00 Immunological update
    G. Silvestri
    13.00 - 13.30 Drug-Drug Interactions
    D. Cattaneo
    13.35-14.50

    Oral Communications

    Basic Science and Immunology

    Oral Communications

    Basic Science and Immunology

    Chairs: C. Agrati, C.M. Mastroianni

      121Reduced probability of achieving optimal viro-immunological condition in subjects with vertical transmission of HIV reaching adult age with unsuppressed HIV RNA or incomplete immunological recovery
    A. Celotti,
      36Immunological recovery in T-cell activation after DAA treatment and SVR in HIV positive subjects with chronic hepatitis C
    F. Maggiolo,
      172Higher frequency of CD4+PD1+ T cells and Interferon-Stimulate Genes are associated to a decrease in CD4+ Treg levels in HIV-1 infected patients
    F. Frasca,
      30Macrophage transcriptome profiling upon CCL2 neutralization identifies an association between activation of antiviral responses and HIV-1 restriction
    L. Fantuzzi,
      310High frequency of Myeloid Derived Suppressor Cells in Immunological Non Responders: possible involvement in CD4 T cell recovery
    A. Sacchi,
      126HIV-binding specificity and -neutralizing potency after ART interruption in chronically HIV-1 infected subjects with long-lasting virological suppression (APACHE study).
    G. Siracusano,
  • Poster Area
    12.15-13.30

    Poster Discussion

    Clinical HIV II

    Poster Discussion

    Clinical HIV II

    Chairs: P. Bassi, R. Bellagamba, V. Giacomet

      56Allogenic hematopoietic stem cell transplantation in HIV-positive recipients: a case series
    C. Oltolini,
      71Italian survey on clinicians' approach to Latent Tubercular Infection in people living with HIV
    L. Caiazzo,
      177A poor immunological recovery is associated with non-AIDS-defining cancers in the era of HAART: a case-control study
    A. Emiliozzi,
      216HPV infection in HIV+, MSM patients followed at a large HIV Clinic in Northern Italy
    E. Asperges,
      335Risk of multiple primary neoplasms and impact on survival of person living with HIV (PLWH)
    V. Mazzotta,
      68Development and standardization of a real time PCR for the quantification of HTLV-1 proviral load
    A. Primavera,
      35Is pretreatment HIV-1 integrase resistance increasing? A large Italian centre experience
    D. Canetti,
      252Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection
    C. Muccini,
      119Evolving epidemiology of HIV/AIDS in Campania Region, 2008-19: is HIV/AIDS population in Campania different?
    F.M. Fusco,
      324Impact of boosted vs unboosted antiretroviral regimen on Dolutegravir plasma and intracellular pharmacokinetics
    M. Ferrara,
    12.15-13.30

    Poster Discussion

    Comorbidities

    Poster Discussion

    Comorbidities

    Chairs: F. Carli, P. Maggi, I. Maida

      51Inflammatory and neurometabolite changes among patients switching away from efavirenz and their correlation with neurotoxicity: results from the sub-study of a randomized controlled trial
    G. Lapadula,
      120Contribution of INSTI, BMI, physical activity or caloric intake to weight gain in PLWH
    G. Dolci,
      137Cerebrospinal Fluid CXCL13 as a marker of Intrathecal Immunoglobulin Synthesis and Immune-activation in treatment-naïve People Living with HIV
    M. Trunfio,
      287Evaluation of the association between cognitive performance and HAND diagnosis with the cognitive reserve in naïve HIV-infected patients
    A.C. Brita,
      234Are Low vitamin D plasma levels associated with intrathecal immuneactivation in PLWH?
    A. Vergori,
      175Gender differences in neurocognitive functions in PLWK
    V. Delle Donne,
      246Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score
    D. Morini,
      230NAFLD phenotype and prevalence across the menopause spectrum in women with HIV
    J. Milic,
      84Incidence of diabetes in a cohort of PLWH people living with HIV in Perugia
    E. Schiaroli,
      203Standard vs higher dose of Rifampicin in patients with tuberculosis: a meta-analysis
    V. Gentile,
    12.15-13.30

    Poster Discussion

    Basic Science and Immunology

    Poster Discussion

    Basic Science and Immunology

    Chairs: L. Butini, S. Piconi

      309DAA treatment fails to restore the inflammatory profile both in HCV/HIV and in HCV infected patients
    C. Agrati,
      79Sterol metabolism modulates susceptibility to HIV-1 Infection
    I. Saulle,
      270Different amounts of activated or exhausted effector memory T cells among differentiated CD4+ or CD8+ T lymphocytes during primary, acute HIV infection
    A. Cossarizza,
      277HIV+ patients: modulating effects of antiretroviral therapy on cytokines' profile and microbiota composition
    G. Nannini,
      352Association between subclinical atherosclerosis and IFN-I response in HIV-1 infected patients
    G. De Girolamo,
      263p53/mir34a/SIRT1 loop and immune reconstitution relationship during chronic HIV infection
    V. Bordoni,
      19Lower Immune Activation in Perinatally than in Horizontally HIV-Infected Adults
    L. Taramasso,
      151Microbiota Composition in HIV-Positive and HIV-Exposed Uninfected Pediatric Subjects
    E. Merlini,
      18Switching to integrase inhibitors is not linked to weight increase in young adults and adolescents perinatally infected with HIV, results from a 10-years observational study
    L. Taramasso,
      143An atypical case of HIV-1 elite controller: 15 years of follow up
    C. Fimiani,
    12.15-13.30

    Poster Discussion

    Social Science and Prevention

    Poster Discussion

    Social Science and Prevention

    Chairs: S. Babudieri, B.M. Celesia, M. Di Benedetto

      104HIV SelfTesting: a survey of self-tests availability in Italian Pharmacies
    M. Maffeo,
      106Testing MSM in cruising venues
    D. Zagato,
      370Behavioral aspects of MSM tested in community-based settings in 5 cities
    M. Breveglieri,
      29Pre-exposure prophylaxis in Modena: a wide spread of sexually transmitted infections among users attending the dedicated outpatient Clinic
    C. Rogati,
      154Prevalence and risk factors for HPV anal infection in PrEP users: implications for vaccination policy
    R. Rossotti,
      112NEETagers for the prevention of HIV and AIDS
    V. Corallino,
      90Clinical research integrated with narrative medicine to understand living and coping with HIV: TMC114FD1HTX4011 - DIAMANTE study
    D. Mancusi,
      292Women and HIV in prison setting: a data up date from the Italian ROSE network
    E. Rastrelli,
      166First-year experience of an HIV clinic-based stop-smoking service
    V. Spagnuolo,
      148Psychiatric disturbances are common in PrEP users: an analysis of comorbidities and comedications in real life
    R. Rossotti,

Plenary session

Special events session

Pre-Conference courses session

Symposium session

Oral Communications session

Oral Poster session

Sponsored session

×
Chiudi